EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods

Sara Carazo iD, Jonathan Phimmasone, Danuta M Skowronski, Katia Giguère, Manale Ouakki iD, Denis Talbot iD, Charles-Antoine Guay, Chantal Sauvageau iD, Nicholas Brousseau iD, Gaston De Serres iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Sara Carazo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec city, QC, Canada. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Health Agency of Canada, Ministère de la Santé et des Services Sociaux du Québec, Fonds de recherche du Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We estimated vaccine effectiveness (VE) against COVID-19 and long COVID during pre-Omicron and Omicron periods, by number of doses and prior infection history.

Methods

We combined survey information from a cohort of healthcare workers in Quebec, Canada, with immunization registry and laboratory administrative data. We defined COVID-19 cases as symptomatic laboratory-confirmed infections and long COVID as self-reported symptoms persisting ≥12 weeks. We assessed VE against COVID-19 and long COVID, stratified by infection history, using a test-negative design where vaccinated participants were compared to unvaccinated participants during the pre-Omicron period or to those twice vaccinated ≥6 months before laboratory testing during the Omicron period.

Results

Analyses included 8230 COVID-19 participants and 43 361 tested specimens. During the pre-Omicron period, 1- and 2-dose VE was 75% (95% CI: 64–83) and 95% (95% CI: 84–98) against COVID-19, respectively, and 91% (95% CI: 79–96) and 87% (95% CI: 22–98) against long COVID, respectively. During the Omicron period, booster dose VE was 41% (95% CI: 34–47) against COVID-19 and 57% (95% CI: 46–66) against long COVID, waning by 6 months. Hybrid VE in vaccinated and previously infected individuals ranged from 81% (95% CI: 38–94) to 92% (95% CI: 87–95) regardless of number of doses, prior infecting variant or median time since last immunological event up to 9 months.

Conclusions

COVID-19 vaccination prevented long COVID during the pre-Omicron period and reduced the risk by more than half post-Omicron. With most of the population by now both vaccinated and infected, repeated booster doses may add little incremental value against long COVID, an observation with important public health, immunization program, and cost implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesVaccine EfficacyHumansMaleFemaleMiddle AgedAdultQuebecSARS-CoV-2VaccinationHealth PersonnelAgedYoung Adult

Stichwörter der Autor:innen

SARS-CoV-2hybrid immunitylong COVIDvaccine effectiveness

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec city, QC, Canada.
  • Research Center, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Quebec City, QC, Canada.
  • Biological Risk Unit, Institut national de santé publique du Québec, Quebec City, QC, Canada.
  • Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, BC, Canada.

ORCID-Profile: Sara Carazo, Manale Ouakki, Denis Talbot, Chantal Sauvageau, Nicholas Brousseau, Gaston De Serres

Förderung

  • Public Health Agency of Canada
  • Ministère de la Santé et des Services Sociaux du Québec
  • Fonds de recherche du Québec

Zitieren

APA

Carazo, S., Phimmasone, J., Skowronski, D. M., Giguère, K., Ouakki, M., Talbot, D., Guay, C. A., Sauvageau, C., Brousseau, N., & De Serres, G. (2026). Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf549

Vancouver

Carazo S, Phimmasone J, Skowronski DM, Giguère K, Ouakki M, Talbot D, et al. Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf549

BibTeX
@article{Carazo2026,
  author = {Carazo, Sara and Phimmasone, Jonathan and Skowronski, Danuta M and Giguère, Katia and Ouakki, Manale and Talbot, Denis and Guay, Charles-Antoine and Sauvageau, Chantal and Brousseau, Nicholas and De Serres, Gaston},
  title = {Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf549}
}
Kostenlos starten →